Health Condition 1: null- All patients clinically diagnosed as Chronic Urticaria aged 18 yrs and above and not responding to a single daily dose of second generation antihistamine after 2 weeks of therapy
Conditions
Interventions
Intervention1: Subcutaneous Injection of Autologous Serum Therapy: Five ml venous blood of the patient will be drawn with a sterile, disposable syringe from the antecubital vein in a sterile Vacutaine
Sponsors
Medical College Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: All patients presenting with chronic urticaria aged above 18 years and symptoms not responding to a single daily dose of second generation antihistamine after 2 weeks of therapy.
Exclusion criteria
Exclusion criteria: Pregnant and lactating ladies Immunosuppressed due to drug or disease Allergy to Cetirizine Concomitant systemic illness requiring treatment Mental illness interfering with perception of urticarial symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effectiveness of subcutaneous autologous serum therapy versus conventional intramuscular serum therapy in cases of chronic urticaria 1. By Urticaria Severity Score (USS) 2. By Total Severity Score (TSS)Timepoint: Baseline, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24, 28 and 32 weeks after randomization | — |
Secondary
| Measure | Time frame |
|---|---|
| A. Safety of two treatment arms 1. By checklist for adverse events 2. CDSCO ADR reporting form 3. Laboratory investigations B. Quality of life in the two treatment arms by Dermatology Life Quality Index (DLQI)Timepoint: Baseline and at 8 weeks and 32 weeks after randomization | — |
Countries
India
Contacts
Public ContactDr Adrija Datta
Department of Dermatology
Outcome results
None listed